Equities researchers at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.
NovaBay Pharmaceuticals Trading Down 11.0 %
NYSE NBY opened at $0.07 on Tuesday. The company’s fifty day simple moving average is $0.13 and its 200-day simple moving average is $0.22. NovaBay Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $1.52. The stock has a market cap of $2.64 million, a P/E ratio of -0.02 and a beta of 1.97.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last posted its earnings results on Tuesday, March 26th. The company reported ($0.95) EPS for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 150.14% and a negative net margin of 65.46%. The firm had revenue of $3.73 million for the quarter. On average, research analysts expect that NovaBay Pharmaceuticals will post -0.41 EPS for the current fiscal year.
Institutional Trading of NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Recommended Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How to Calculate Inflation Rate
- Merger or Not, Albertson’s Companies is a Good Buy
- Investing in large cap stocks: Diving into big caps
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.